Nuclidium AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nuclidium AG - overview
Established
2017
Location
Basel, -, Switzerland
Primary Industry
Biotechnology
About
Founded in 2017 and based in Basel, Switzerland, Nuclidium AG, formerly known as Swiss Nuclides AG, operates as a biopharmaceutical company that develops and manufactures drugs for the treatment of cancer. Leila Jaafar (CEO) and Gustav von Schulthess are the co-founders of the company. In July 2025, Nuclidium AG raised CHF 79 million in series B funding co-led by Kurma Partners, Angelini Ventures, Wellington Partners, and Neva, with participation from DeepTech and Climate Fund, Bayern Kapital, HighLight Capital, Eurazeo, Vives, NRW Bank, and other unspecified investors. The company offers CuTrace™ platform, which integrates copper radiometals with a variety of cancer-targeting compounds to generate novel therapeutic and diagnostic solutions.
Nuclidium’s pipeline include NuriPro ™ for prostate cancer, TraceNET ™ for neuroendocrine tumors, Kalios ™ for colorectal, gastric, and lobular breast cancer, CuNeo ™ for ductal breast and lung cancer, and AlphaFlare ™ for head and neck pancreatic cancer. The firm’s pipeline comprises of tumor indications and copper-based radiopharmaceuticals.
Current Investors
Turos Capital, Wellington Partners, Eurazeo
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.nuclidium.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.